GGrantIndex
← Leaderboards

Zaneta Nikolovska-Coleska

University Of Michigan At Ann Arbor

Google Scholar ↗PubMed ↗ORCID ↗
$5,411,857
Attributed
$8,664,957
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $809.7K · FY2006–25
$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,664,957 · 8

By mechanism

R01$4,126,504 · 2
T32$2,565,064 · 2
R21$1,036,818 · 3
R33$936,571 · 1

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsLeadBiochemicalDesignStructureAnalogBaseResistanceCancer CellApoptosisHigh Throughput ScreeningProtein FamilyChemotherapyProteinsInhibitor/AntagonistSeriesSmall MoleculeAffinityIn VivoResponseIn VitroPharmaceutical PreparationsStructure-Activity RelationshipCells

Grant awards (28)

Targeting the longevity regulator PAPP-A with small molecule inhibitors$456,502
R33 · FY2025 · AG · contact PI
Training Program in Translational Research$321,270
T32 · FY2025 · GM
Targeting the longevity regulator PAPP-A with small molecule inhibitors$480,069
R33 · FY2024 · AG · contact PI
Training Program in Translational Research$329,616
T32 · FY2024 · GM
Training Program in Translational Research$318,321
T32 · FY2023 · GM
Targeting the longevity regulator PAPP-A with small molecule inhibitors$186,520
R21 · FY2023 · AG · contact PI
Training Program in Translational Research$312,217
T32 · FY2022 · GM
Targeting the longevity regulator PAPP-A with small molecule inhibitors$237,891
R21 · FY2022 · AG · contact PI
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer$516,652
R01 · FY2021 · CA · contact PI
Training Program in Translational Research$292,577
T32 · FY2021 · GM
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer$516,593
R01 · FY2020 · CA · contact PI
Training Program in Translational Research$241,028
T32 · FY2020 · GM
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer$501,374
R01 · FY2019 · CA · contact PI
Training Program in Translational Research$190,645
T32 · FY2019 · GM
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer$516,449
R01 · FY2018 · CA · contact PI
Training Program in Translational Research$188,520
T32 · FY2018 · GM
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer$529,087
R01 · FY2017 · CA · contact PI
Training Program in Translational Research$186,446
T32 · FY2017 · GM
Training Program in Translational Research$184,424
T32 · FY2016 · GM
Novel selective small-molecule inhibitors of Mcl-1 protein$300,858
R01 · FY2014 · CA · contact PI
Novel selective small-molecule inhibitors of Mcl-1 protein$291,575
R01 · FY2013 · CA · contact PI
Novel selective small-molecule inhibitors of Mcl-1 protein$310,210
R01 · FY2012 · CA · contact PI
Novel Mcl-1 inhibitors for Pancreatic Cancer Therapy$168,205
R21 · FY2012 · CA · contact PI
Novel selective small-molecule inhibitors of Mcl-1 protein$310,232
R01 · FY2011 · CA · contact PI
Novel Mcl-1 inhibitors for Pancreatic Cancer Therapy$215,577
R21 · FY2011 · CA · contact PI
Novel selective small-molecule inhibitors of Mcl-1 protein$333,474
R01 · FY2010 · CA · contact PI
Discovery and characterization of novel small molecule inhibitors of Mcl-1$38,625
R21 · FY2008 · NS · contact PI
Discovery and characterization of novel small molecule inhibitors of Mcl-1$190,000
R21 · FY2006 · NS · contact PI